A placebo-controlled trial of mirtazapine for the management of methamphetamine withdrawal
A placebo-controlled trial of mirtazapine for the management of methamphetamine withdrawal
复制标题
DOI：
10.1080/09595230801935672
复制
发表时间：
2008-01-01
影响因子：
3.8
通讯作者：
Shand, Diana
中科院分区：
文献类型：
--
作者：
Cruickshank, Christopher C.;Montebello, Mark E.;Shand, Diana
介绍和目标。作为一种具有镇静和抗焦虑特性的抗抑郁药，米氮平可能是甲基苯丙胺戒断的适当药物治疗。本研究旨在检查米氮平是否改善了门诊患者的记忆保留并缓解了甲基苯丙胺戒断症状。设计和方法。进行了一项米氮平治疗甲基苯丙胺戒断的门诊患者双盲、随机安慰剂对照试验（15 mg米氮平治疗2天，30 mg米氮平治疗12天）。两组均接受叙事治疗咨询。在第0、3、7、14和35天记录的指标包括：治疗保持率、安非他明戒断症状评估、雅典抑郁量表、简明症状量表、抑郁-焦虑-压力量表（DASS）、依赖严重程度量表和阿片治疗指数药物使用子量表。结果招募了31名参与者（18名安慰剂，13名米氮平），52%的人完成了2周的药物治疗阶段。米氮平组和安慰剂组之间在保持或任何症状测量方面没有显著差异，除了米氮平组在基线时测量到更大的DASS焦虑和更长的睡眠时间。讨论和结论。结果表明，米氮平不促进保留或招募门诊甲基苯丙胺戒断治疗，虽然招募可能已不足以确定一个显着的治疗效果。叙事疗法对甲基苯丙胺依赖患者的潜在作用值得进一步探讨。
Introduction and Aims. As an antidepressant with sedative and anxiolytic properties, mirtazapine may be an appropriate pharmacotherapy for methamphetamine withdrawal. This study sought to examine whether mirtazapine improves retention and alleviates methamphetamine withdrawal symptoms in an out-patient setting. Design and Methods. An out-patient double-blind, randomised placebo-controlled trial of mirtazapine for the treatment of methamphetamine withdrawal was conducted (15mg nocte for 2 days, 30mg nocte for 12 days). Both groups were offered narrative therapy counselling. Measures recorded on days 0, 3, 7, 14 and 35 included: treatment retention, Amphetamine Cessation Symptoms Assessment, the Athens Insomnia Scale, the Brief Symptom Inventory, the Depression-Anxiety-Stress Scale (DASS), Severity of Dependence scale and the Opiate Treatment Index Drug Use subscale. Results. Thirty-one participants were recruited (18 placebo, 13 mirtazapine) and 52% completed the 2-week medication phase. No significant differences between the mirtazapine and placebo groups in retention, or any symptom measure were observed, except greater DASS-anxiety and longer sleep duration were measured at baseline among the mirtazapine group. Discussion and Conclusions. Results suggest that mirtazapine does not facilitate retention or recruitment in out-patient methamphetamine withdrawal treatment, although recruitment may have been insufficient to identify a significant treatment effect. The potential role of narrative therapy for methamphetamine dependent patients deserves further exploration.